This study aims to describe quality of life in hereditary or acquired non drug-related bradykinin-mediated angioedema patients, using validated questionnaires

Inclusion Criteria:

• Clinically documented angioedema due to C1 inhibitor deficiency, hereditary (type I et II) or acquired
• Clinically documented angioedema with normal C1 inhibitor activity (hereditary type III)

Exclusion Criteria:

• Acquired angioedema with normal C1 inhibitor activity (former "drug-induced")
• Minor subjects
• Vulnerable subjects (under guardianship/curatorship/tutorship)
• Pregnant women

Hereditary or Acquired non drug-induced bradykinin-mediated angioedema patients